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Abstract: Survivin is a member of the family of proteins, which inhibit apoptosis (inhibitor of apoptosis proteins - IAP).
Expression of survivin was found in colorectal cancer, neuroblastoma, bladder cancer, non-small cell lung cancer, and breast
cancer. There is some recent data indicating the correlation of poor prognosis and worse response to chemotherapy in patients
with oesophageal squamous cell carcinoma (OSCC) expressing survivin. The aim of the present study was to assess survivin
expression in cancerous tissue of patients with advanced OSCC and to test the potential correlation between survivin expression
and clinicopathological data. Forty two patients (mean age 58.36±8.97 yrs), who were oesophagectomised due to squamous
cell carcinoma of the thoracic oesophagus between 1998 and 2000, were retrospectively analysed. Cytoplasmic survivin
expression, examined immunohistochemically, was found in 35 (83.33%) cases. No statistically significant correlation between
survivin expression in the tumour and patients’ gender, TNM stage, or vascular involvement was noted. The mean survival of
patients with cytoplasmic survivin expression (17.81±5.51 months) was not statistically different to those with negative survivin
staining (16±6.28 months) as assessed by Mantel-Cox test (p=0.49). Univariate regression analysis revealed UICC staging as
the only predictor of survival in the analysed group (p<0.05). These results indicate that the cytoplasmic survivin expression
does not seem to be the prognostic factor in advanced cases of OSCC.
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Introduction
Survivin is a new member of the family of proteins,
which inhibit apoptosis (inhibitor of apoptosis proteins
- IAP) [12, 15, 17]. It has been shown to directly inhibit
terminal protease effectors of apoptosis, i.e. caspase-3
and caspase-7 [6, 12, 17, 19]. There is a growing body
of evidence indicating that survivin plays an important
role in inhibition of apoptosis in cells exposed to diverse
apoptotic stimuli by associating with microtubules of
mitotic spindles. Loss of control over defects in the
structure of mitotic spindle and/or in chromosome con-
figuration during cell division caused by survivin is
responsible for its antiapoptotic action [11].
Expression of survivin was found in colorectal
cancer, neuroblastoma, bladder cancer, non-small cell
lung cancer, or breast cancer [1, 2, 10, 13, 15, 16, 18].
There is some recent data indicating the correlation of
poor prognosis and worse response to chemotherapy in
patients with oesophageal squamous cell carcinoma ex-
pressing survivin [3, 4, 6, 7].
The aim of the present study was to assess survivin
expression in cancerous tissue of patients with advanced
oesophageal squamous cell carcinoma and to test the
potential correlation between survivin expression and
some selected clinicopathological parameters such as
depth of tumour invasion, lymph node involvement, or
overall survival.
Materials and methods
Patients. Forty two patients oesophagectomised at the 2nd Depart-
ment of General Surgery, Skubiszewski Medical University, Lublin,
between 1998 and 2000, were analyzed. In all these patients the
diagnosis of squamous cell carcinoma of the thoracic oesophagus
was confirmed histopathologically. The analysed group included 38
men and 4 women, with male to female ratio 9.5/1. The age of the
patients ranged from 40 to 70 yrs (mean 58.36±8.97). Neither neoad-
juvant chemo- nor radiotherapy was applied before surgery. No
adjuvant chemotherapy was applied in this group. Patients who died
of postoperative complications within 30 days - (7) and lost in
follow-up (6) were excluded from survival analysis. The clinicopa-
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thological data of all patients who underwent surgery are shown in
Table 1. Patients who smoked at least 20 cigarettes a day (smokers)
and drank at least 20 g of ethanol daily for 5 or more years were
assessed separately.
Immunohistochemistry. Paraffin-embedded tumour specimens
were examined. Four-µm sections were mounted on slides precoated
with poly-L-lysine (SIGMA). Deparaffinized sections were im-
mersed in citrate buffer (0.01 M, pH 6.0), heated in a microwave oven
to 100˚C twice for 5 min in order to retrieve the antigens, and then
allowed to cool down for 45 min in the same buffer. Next, the slides
were rinsed thoroughly with deionised water and PBS, incubated
with serum-free blocking solution (DAKO) and primary antibody
was applied for 60 min at room temperature. Rabbit anti-human
survivin antibody (200 µg/mL, Santa Cruz Biotechnology) was used
pre-diluted 1:20 in blocking buffer. The negative controls, obtained
by substitution of the primary antibody with blocking buffer, were
also included in the study. Incubation with secondary antibody and
product visualization was performed employing LSAB2 Kit
(DAKO) with AEC Substrate-Chromogen, according to the manu-
facturer’s protocol. Specimens were counterstained with Mayer’s
hematoxylin for 2 min, washed with deionised water and mounted
in Glycergel (DAKO). The slides were examined under Olympus
BH2 light microscope, fitted with S Plan Apo × 100 immersion
objective. The cases were scored as survivin-positive when more
than 5% of the cells reacted with the anti-survivin antibody, as
proposed by Kawasaki et al. [8] (Fig. 1).
Statistical analysis. The obtained results were mostly analysed as
dichotomised variables: tumour stage T3 vs. T4; lymph node invol-
Fig. 1. Immunohistochemical detection of survivin in oesophageal cancer. Survivin-negative (A) and survivin-positive (B) cancer cells
showing cytoplasmic immunostaining. 
Fig.  2. Cumulative proportion sur-
viving of the patients with positive
and negative cytoplasmic survivin
expression.
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vement N0 (-) vs. N1-N2 (+); remote metastases M0 vs. M1; blood
vessels involvement (+) vs. (-). The Spearman nonparametric corre-
lation test or U-Mann-Whitney test for two independent probes were
used for statistical comparison of the results. Overall survival was
assessed by the Kaplan-Meier method. The significance of differen-
ces in overall survival was calculated by the Mantel-Cox test. The
differences were considered to be significant for p<0.05. All statis-
tical analyses were performed using SPSS software (Statistica).
Results 
Cytoplasmic survivin expression in tumour cells was
detected in 35 (83,33%) cases of oesophageal squamous
cell carcinoma. Nuclear survivin expression was not
observed in the examined tumour specimens. No statis-
tically significant correlation between cytoplasmic sur-
vivin expression in the tumour and patient’s gender,
TNM stage, or vascular involvement was noted.  No
correlation was found, either, between cytoplasmic sur-
vivin expression and tobacco smoking. Lower cytoplas-
mic survivin expression was noted in patients with
history of chronic alcohol intake but this trend did not
reach statistical significance (p=0.08). The results are
shown in Table 1.
Kaplan-Meier survival curves for patients with
oesophageal squamous cell carcinoma categorised ac-
cording to survivin expression are shown in Figure 2.
The mean survival of patients with cytoplasmic survivin
expression (17.8 months±15.51) was not statistically
different to those with negative survivin staining (16
months±6.28) according to Mantel-Cox test (p=0.49).
Univariate regression analysis revealed UICC staging as
the only predictor of survival (p<0.05). The other par-
ameters did not reach statistical significance. 
Discussion
Recent studies indicating the role of survivin in carci-
nogenesis of OSCC became the inspiration to perform
the present analysis [3, 4, 6, 7]. Survivin is one of the
apoptosis inhibitor proteins and participates in the regu-
lation of cell division. It has apoptotic control over G2-M
checkpoint of the cell cycle [3, 6, 11, 17]. Survivin
expression seems to be specific for neoplasms, but not
for nonproliferating adult tissues [1, 2, 6, 10, 15, 17, 18].
Anti-survivin proteins are observed in serum of patients
with malignant neoplasms more frequently than p53
protein [8].
In the present study, 42 patients treated surgically due
to advanced, thoracic oesophageal squamous cell carci-
noma were analysed. The vast majority of patients in-
cluded in the study were classified at III or IV stage of
disease according to UICC classification. Cytoplasmic
expression of survivin was noted in 35 subjects (83.3%).
Grabowski and co-workers [4] were the first who dif-
ferentiated nuclear and cytoplasmic expression of sur-
vivin  and descr ibed i ts  translocation during
carcinogenesis. They observed cytoplasmic and nuclear
survivin expression in 67% and 80% of cancer patients
respectively. Lack of nuclear survivin expression in
tumour specimens examined in this study can be caused
by the type of antibodies applied which were different
from those used by Grabowski et al. [4]. In studies
concerning other tumours, expression of survivin was
noted at the level of 70.7% in breast cancer, 34.5% in
gastric cancer, and 53.2% in colorectal cancer [14, 15, 18].
In the present study, no statistical correlation was
found between cytoplasmic survivin expression and the
analysed parameters, i.e. the depth of invasion, lymph
node metastases and remote metastases. Statistical
correlation between cytoplasmic survivin expression
and overall survival revealed no significant differences
between survivin-positive and -negative OSCC cases.
These data are very similar to those obtained by other
research groups. Ikeguchi et al. [6] revealed no correla-
Table 1. Clinicopathological data of patients and tumours according
to cytoplasmic survivin expression
Patients Cytoplasmic survivin
N (%) expressio
n  (+) (%) P value
Total
 Male
 Female
42
38
4
100
90.47
9.53
35
31
4
83.33
81.57
100
0.57 (n.s.)
T-stage
 T3
 T4
26
16
61.90
38.10
21
13
80.76
81.25
0.86 (n.s.)
N-stage
 N(-)
 N(+)
10
32
23.80
76.19
9
26
90
81.25
0.528  (n.s.)
M-stage
 M0
 M1
34
8
80.95
19.04
29
6
85.29
75
0.49 (n.s)
Vascular 
involvement
 (+)
 (-)
32
10
76.19
23.81
26
9
81.25
90
0.52 (n.s.)
Differentiation
 G1-G2
 G3
28
14
66.6
33.3
24
11
85.7
78.57
0.58 (n.s)
UICC-stage
 II
 
 
 III
 IV
3
31
8
7.14
73.80
19.04
3
27
6
100
87.09
75
0.63 (n.s.) vs. IV
0.68 (n.s.) vs. II
0.72 (n.s.) vs. III
Tobacco
 (+)
 (-)
35
7
83.33
16.66
28
7
80
100
0.20 (n.s.)
Alcohol
 (+)
 (-)
31
11
73.80
26.20
24
11
77.41
100
0.08 (n.s.)
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tion between survivin mRNA expression and lymph
node metastases or depth of tumour invasion in OSCC.
Sarela et al. [15] drew the same conclusions in colorectal
cancer. In the later study, Ikeguchi et al. [5] confirmed
the previous results and showed no correlation between
the level of survivin expression and the occurrence of
apoptosis or tumour angiogenesis. However, sur-
vivin/GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) ratio positively correlated with proliferative
activity and p53 nuclear accumulation in cancer cells.
Grabowski et al. [4] noted that cytoplasimc survivin
staining has no prognostic relevance in OSCC. In con-
trast, significant correlation was observed between nu-
clear survivin expression and lymph node involvement,
tumour grading or overall survival. In other study, sur-
vivin mRNA expression in oesophageal cancer cells (51
cases) assessed with the use of RT-PCR was significant-
ly higher than in the adjacent normal tissue. Further-
more, pN4 tumours showed significantly higher survivin
expression comparing to pN0-3 ones [7] . Interestingly,
longer median survival was noted in "survivin-negative"
patients than in "survivin-postitve" group with oesoph-
ageal cancer, as well as with other malignancies [3, 4, 6,
7, 15]. Some other reports indicate association of posi-
tive nuclear survivin staining with a favourable prog-
nosis in gastric or breast cancer [9, 14]. Kato et al. [7]
suggest some caution in the interpretation of these re-
sults indicating  very short follow-up and small number
of patients included in the analyses. 
In the present study, the obtained results seem to be
different from those mentioned above. Certainly, the
results were influenced by specificity of the analysed
group of patients, which was quite similar regarding the
advanced stage of the disease (mostly III or IV UICC
grade). It should be emphasized that the majority of
patients with OSCC in Poland is diagnosed and treated
at advanced stage of the disease, so the analysed group
seems to be representative for this country.
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